Three concerns with regards to the utilization of COX-2 inhibitor (celecoxib) in combination with standard chemoradiotherapy for nasopharyngeal carcinoma

Journal of Cancer Research and Therapeutics

Volumn 8, Issue 3, 2012, Pages 464-465

  Revannasiddaiah, Swaroop ^a   Gupta, Manoj ^a   Seam, Rajeev ^a   Rastogi, Madhup ^a  

^a INDIRA GANDHI MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTINEOPLASTIC AGENT; CELECOXIB; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID;

ADENOMA; CANCER COMBINATION CHEMOTHERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL PROTOCOL; DRUG WITHDRAWAL; HEART INFARCTION; HUMAN; LETTER; MUCOSA INFLAMMATION; NASOPHARYNX CARCINOMA; ODYNOPHAGIA; RADIATION INJURY; SURVIVAL;

CHEMORADIOTHERAPY; CISPLATIN; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; HUMANS; MALE; NASOPHARYNGEAL NEOPLASMS; PYRAZOLES; SULFONAMIDES;

EID: 84873336006     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/0973-1482.103540     Document Type: Letter

References (5)

1. Mohamma-Dianpanah M, Razmjou-Ghalaei S, Shafizad A, Ashouri-Taziani Y, Khademi B, Ahmadloo N, et al. Efficacy and safety of concurrent chemoradiation with weekly cisplatin ± low-dose celecoxib in locally advanced undifferentiated nasopharyngeal carcinoma: A phase II-III clinical trial. J Can Res Ther 2011;7:442-7.
2. Hawkey CJ. COX-2 inhibitors. Lancet 1999;353:307-14.
3. Goppelt-Struebe M, Wolter D, Resch K. Glucocorticoids inhibit prostaglandin synthesis not only at the level of phospholipase A2 but also at the level of cyclo-oxygenase/PGE isomerase. Br J Pharmacol 1989;98:1287-95.
4. Solomon SD, Wittes J, Finn PV, Fowler R, Viner J, Bertagnolli MM, et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 2008;117:2104-13.
5. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80.